KYMERA THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense
KYMERA THERAPEUTICS, INC. (KYMR) had Deferred Tax Assets, Tax Deferred Expense of $18.63 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpense · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense $18.63M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense $18.79M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense $13.64M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense $10.35M.
| Period end | Deferred Tax Assets, Tax Deferred Expense |
|---|---|
| 2025-12-31 | $18.63M 10-K · filed 2026-02-26 |
| 2024-12-31 | $18.79M 10-K · filed 2026-02-26 |
| 2023-12-31 | $13.64M 10-K · filed 2025-02-27 |
| 2022-12-31 | $10.35M 10-K · filed 2024-02-22 |
| 2021-12-31 | $5.16M 10-K · filed 2023-02-23 |
| 2020-12-31 | $1.59M 10-K · filed 2022-02-24 |
| 2019-12-31 | $525.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |